Understanding why specific neurons die in Huntington's disease — and precisely when their molecular identity begins to erode — has been one of the field's most stubborn challenges. A new temporal transcriptomic atlas now offers the most granular cell-by-cell account yet of how corticostriatal circuits deteriorate across disease stages, with potential implications for the timing of future therapeutic interventions.
Using single-nucleus RNA sequencing, researchers mapped gene expression across striatum and motor cortex in heterozygous zQ175 knock-in mice — a full-length huntingtin model — at two defined disease stages: early symptomatic (6 months) and late symptomatic (18 months). The zQ175 CAG repeat length was chosen deliberately to place cells beyond the somatic expansion threshold linked to transcriptional dysregulation in vulnerable human neuronal populations, yet before the catastrophic de-repression and overt cell loss seen at extreme expansions. By modeling genotype-dependent effects statistically, the team separated bona fide disease signatures from normal aging and compensatory transcriptional responses at single-cell resolution across interconnected cortical and striatal populations.
This work is editorially significant for two reasons. First, most prior single-cell HD studies used rapidly progressing fragment models (e.g., R6/2) that compress pathology into weeks, obscuring the temporal sequence of molecular events. The zQ175 full-length model allows a more human-relevant, protracted disease arc. Second, the dual-region, two-timepoint design enables differentiation of which cell types lose transcriptional identity early versus late — a distinction critical for pinpointing therapeutic windows. The key limitation is that mouse models inevitably diverge from human HD; somatic CAG expansion dynamics, human-specific striatal cell subtypes, and the decades-long human disease course cannot be fully recapitulated. Nonetheless, as a resource for generating mechanistic hypotheses and prioritizing cell targets, this atlas represents a meaningful advance over single-timepoint or single-region profiling approaches. Its value will ultimately depend on how well the identified stage-specific signatures validate in human post-mortem or iPSC-derived data.